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Staphylococcus aureus infection causes oxidative stress in neutrophils. The immune cells use reactive oxygen species (ROS) for
carrying out their normal functions while an excess amount of ROS can attack cellular components that lead to cell damage. The
present study was aimed to test the protective role of nanoconjugated vancomycin against vancomycin-sensitive Staphylococcus
aureus (VSSA) and vancomycin-resistant Staphylococcus aureus (VRSA) infection induced oxidative stress in neutrophils.
VSSA- and VRSA-infection were developed in Swiss mice by intraperitoneal injection of 5 × 106 CFU/mL bacterial solutions.
Nanoconjugated vancomycin was treated to VSSA- and VRSA-infected mice at its eﬀective dose for 10 days. Vancomycin was
treated to VSSA and VRSA infected mice at similar dose, respectively, for 10 days. The result reveals that in vivo VSSA and VRSA
infection signiﬁcantly increases the level of lipid peroxidation, protein oxidation, oxidized glutathione level, and nitrite generation
and decreases the level of reduced glutathione, antioxidant enzyme status, and glutathione-dependent enzymes as compared to
control group; which were increased or decreased signiﬁcantly near to normal in nanoconjugated vancomycin-treated group.
These ﬁnding suggests the potential use and beneﬁcial protective role of nanoconjugated vancomycin against VSSA and VRSA
infection induced oxidative imbalance in neutrophils.
1.Introduction
Staphylococcus aureus is a major human pathogen causing
large variety of infections worldwide with prevalence rate
ranging from 4.6–54.4% [1–5]. S. aureus causes superﬁcial
skin infections to life-threatening diseases such as endocar-
ditis, sepsis and soft tissue, urinary tract, respiratory tract,
intestinaltract,andbloodstreaminfections[6,7].Theability
ofS.aureustosurviveintheeukaryoticintracellularenviron-
ment could explain several aspects of chronic staphylococcal
diseases and long-term colonization. Internalization may
provide a mean of protection against host defenses and
certain classes of antibiotics. Staphylococcal infections are
typically associated with death of tissue, and evidence sug-
gests intracellular bacteria are capable of inducing apoptosis.
S. aureus-mediated apoptosis has been reported in epithelial
cells[8–10],keratinocytes[11],endothelialcells[12,13],and
osteoblasts [14]. Wesson et al. demonstrated host caspases-
8 and -3 to play a role in S. aureus-induced apoptosis, and
caspase-8 is known to be associated with apoptosis trig-
gered by engagement of death receptors [10]. Resistance of
S. aureus to antibiotics appeared within a few years after
the onset of the antibiotic era [15], and this problem has
reached epic proportions owing to overuse and improper
use of anti-biotics [16]. S. aureus resistance to antibiotics
currently spans all known classes of natural and synthetic
compounds[17].IncreasingresistanceofS.aureustolastline
of drug, that is, vancomycin highlights the need for either
the development of new and novel antibiotics [18, 19]o r
the improvement of eﬃcacy of established antibiotics by the2 ISRN Pharmacology
development of new agents capable of enhancing antibiotic
activity [20].
Chitin, a natural biopolymer, is the major structural
component of invertebrates like crab, shrimp, shells, and the
cell walls of fungi. Chitosan (CS), the deacetylated form of
chitin, is a linear polysaccharide, composed of glucosamine
and N-acetyl glucosamine linked in a β linkage [21–24]. Car-
boxymethyl chitosan (CMC) is a linear polysaccharide com-
posed of β (1,4) glycosidic linkages between 6-carboxym-
ethyl-d-glucosamine monomers. CMC is synthesized from
CS by carboxylation of the hydroxyl and amine groups
[25]. In our previous laboratory report, we synthesized
CMC-EDBE-FA nanoparticle based on carboxy methyl chi-
tosan tagged with folic acid by covalently linkage through
2,2 (ethylenedioxy)bis-(ethylamine), vancomycin was load-
ed onto it, complex is called “nanoconjugated vancomycin”
and observe it’s bactericidal activity against S. aureus [26]. In
our recent laboratory report, we reported that CMC-EDBE-
FA nanoparticle is nontoxic [27]. We also reported that in
vivo challenge of VSSA and VRSA for ﬁve days can produce
the highest degree of damage in lymphocytes through the
increased production of nitric oxide, TNF-α that leads to
decreased antioxidant status in cell and ten days successive
treatment of nanoconjugated vancomycin also eliminate in
vivo VSSA and VRSA infection [28]. Recently, we reported
that, nanoconjugated vancomycin can be used as a potent
free-radical scavenger antioxidative product and can be used
as a potential therapeutic agent against staphylococcal infec-
tion [29]. The present study was aimed to test the protective
role of nanoconjugated vancomycin against VSSA and VRSA
induced oxidative imbalance in neutrophils.
2.MaterialsandMethods
2.1. Chemicals and Reagents. Histopaque 1077, dextran, So-
dium dodecyl sulfates (SDS), 2,4-dinitrophenyl hydrazine
(DNPH), 5 ,5 -dithio(bis)-2-nitrobenzoic acid (DTNB),
standard reduced glutathione (GSH), glutathione reductase
(GR), NADPH Na4, NADPH, oxidized glutathione (GSSG),
agarose, folic acid (FA), Chitosan (medium molecular
weight), dicyclohexyl carbodiimide (DCC), Triﬂuoroacetic
acid,2,2 -(ethylenedioxy)-bis-(ethylamine)(EDBE),di-tert-
butyldicarbonate (BoC2O), N-hydroxysuccinimide (NHS),
and 1-[3-dimethylamino)propyl]-3-ethylcarbodiimide Hy-
drochloride (EDC) were purchased from Sigma Chemical
Co., USA. Sodium chloride (NaCl), sodium dodecyl sulfate,
ethylene diamine tetra acetate (EDTA), tryptic soy broth,
luria broth, mannitol salt agar, agar powder, sucrose, magne-
sium chloride (MgCl2), and sodium azide (NaN3)w e r ep u r -
chased from Himedia, India. Tris-Hcl, Trisbuﬀer, potassium
dihydrogen phosphate (KH2PO4), dipotassium hydrogen
phosphate (K2HPO4), sodium hydroxide (NaOH), sodium
acetate, ammonium acetate, alcohol, sulfanilamide, phos-
phoric acid, and N-C-1 naphthyl ethylene diamine dihy-
drochloride and other chemicals were procured from Merck
Ltd., SRL Pvt. Ltd., and Mumbai, India. All other chemicals
were from Merck Ltd., SRL Pvt., Ltd., and Mumbai and were
of the highest grade available.
2.2. Animals. Experiments were performed using Swiss male
mice 6–8 weeks old, weighing 20–25g. The animals were
fed standard pellet diet and water were given ad libitum and
housed in polypropylene cage (Tarson) in the departmental
animal house with 12h light:dark cycle and the temperature
of 25 ± 2◦C. The animals were allowed to acclimatize for one
week. The animals used did not show any sign of malignancy
or other pathological processes. Animals were maintained in
accordance with the guidelines of the National Institute of
Nutrition, Indian Council of Medical Research, Hyderabad,
India and approved by the ethical committee of Vidyasagar
University.
2.3. Bacterial Strain. We used coagulase positive vancomycin
sensitive (MMC-6) and resistant (MMC-17) Staphylococcus
aureus strains that were isolated from human post-operative
pus sample [30]. These bacterial strains were grown at 37◦C
for overnight in tryptic soy broth. The bacterial culture
was centrifuged at 15,000rpm for 15min. The pellet was
resuspended and washed with sterile phosphate buﬀer saline
(PBS). Using a UV-spectrophotometer (Schimadzu, USA) at
an absorbance of 620nm, we adjusted the viable bacterial
count to approximately 1.0 × 109 colony-forming units
(CFU)/mL, which corresponded to an optical density of 1.6.
The bacterial suspension was adjusted by serial dilution in
phosphate buﬀer saline (PBS) to give a ﬁnal concentration
of approximately 5 × 106 in 100μL of bacterial suspension
[31].
2.4. Development of VSSA and VRSA Infection in Swiss Mice.
VSSA and VRSA infection was developed in male Swiss
mice by intraperitoneal (i.p.) injection of 100μLo fb a c t e r i a l
suspension containing 5 × 106 CFU/mL according to our
previous laboratory report [28].
2.5. Preparation of CMC-EDBE-FA Nanoparticle and Loading
of Vancomycin. CMC-EDBE-FA nanoparticle was prepared
and vancomycin was loaded onto it according to our previ-
ous laboratory report [26].
2.6. Experimental Design. VSSA- and VRSA-infected mice
were treated with nanoconjugated vancomycin for successive
10daysatadoseof100mg/kgbw/dayand500mg/kgbw/day,
respectively. The dose and duration of nanoconjugated van-
comycin were selected from our previous laboratory report
[28]. The following groups were considered for the experi-
ment:
Group I: control;
Group II: VSSA-infected control;
Group III: VSSA infection + 100mg/kgbw/day van-
comycin;
Group IV: VSSA infection + 100mg/kgbw/day nano-
conjugated vancomycin;
Group V: VRSA-infected control;
Group VI: VRSA infection + 500mg/kgbw/day van-
comycin;ISRN Pharmacology 3
Group VII: VRSA infection + 500mg/kgbw/day na-
noconjugated vancomycin.
After the termination of experiment, animals were sacriﬁced
by an intraperitoneal injection of sodium pentobarbital (60–
70mg/kg body weight) [32] and blood (n = 6/group) was
used for preparation neutrophils for biochemical estimation
of diﬀerent oxidative parameters.
2.7. Separation of Neutrophils. Heparinized blood samples
were used for the separation of neutrophils. Blood samples
were diluted with equal amount of PBS (pH 7.0) buﬀer and
then layered very carefully on the density gradient (Histo-
paque 1077, Sigma Chemical Co.) in 1:2 ratio. Centrifuged
at 500g for 20min and the white milky layer of mononuclear
cells that is lymphocytes was carefully removed. Neutrophils
were isolated from buﬀy coat with RBC layer followed by
dextran sedimentation and hypotonic lysis to remove red
blood cells. The pellets of neutrophil were lysed in a hypo-
tonic lysis buﬀer for 45min at 37◦Ca n dk e p ta t−86◦C until
biochemical estimations of diﬀerent parameters [33].
2.8. Biochemical Estimation
2.8.1. Nitrite (NO) Production by Neutrophils. NO gener-
ation in cell lysate was assessed according to Sanai et al.
1998, with slight modiﬁcation [34]. Sodium nitroprusside
(100mM), in phosphate-buﬀered saline, was mixed with
200μL sample and incubated at room temperature for
150min. After that, Griess reagent (0.5mL) (Containing 1%
sulfanilamide in 5% phosphoric acid and 0.1% N-C-1
naphthyl ethylene diamine dihydrochloride in 1:1 ratio)
was added and incubated at room temperature for 10min.
The absorbance of the chromophore formed was read at
550nm with a double beam Hitachi U2001 UV/Visible spec-
trophotometer (USA). NO generation was calculated using
the sodium nitrite standard curve and expressed as μmol/mg
protein.
2.8.2. Determination of Lipid Peroxidation (MDA) in Neu-
trophils. Lipid peroxidation was estimated by the method of
Ohkawa et al. in cell lysate [35]. Brieﬂy, the reaction mix-
ture contained Tris-HCl buﬀer (50mM, pH 7.4), tertbutyl
hydroperoxide (BHP) (500μM in ethanol) and 1mM FeSO4.
After incubating the samples at 37◦C for 90min, the reaction
was stopped by adding 0.2mL of 8% sodium dodecyl sulfate
(SDS) followed by 1.5mL of 20% acetic acid (pH 3.5).
The amount of malondialdehyde (MDA) formed during
incubationwasestimated byadding 1.5mLof 0.8%TBAand
furtherheatingthemixtureat95◦Cfor45min.Aftercooling,
samples were centrifuged, and the TBA reactive substances
(TBARS) were measured in supernatants at 532nm by us-
ing 1.53 × 105 M−1 cm−1 as extinction coeﬃcient. The levels
of lipid peroxidation were expressed in terms of nmol/mg
protein.
2.8.3. Protein Carbonyls (PC) Contents in Neutrophils. Pro-
tein oxidation was monitored by measuring protein carbonyl
contents by derivatization with 2,4-dinitrophenyl hydrazine
(DNPH) [36]. In general, cell lysate proteins in 50mM
potassium phosphate buﬀer, pH 7.4, were derivatized with
DNPH (21% in 2N HCl). Blank samples were mixed with
2NHClincubatedat1hinthedark;proteinwasprecipitated
with20%trichloroaceticacid(TCA).Underivatizedproteins
were washed with an ethanol:ethyl acetate mixture (1:1).
Final pellets of protein were dissolved in 6.0N guanidine
hydrochlorideandabsorbancewasmeasuredat370nm.Pro-
tein carbonyls content was expressed in terms of nmol/mg
protein.
2.8.4. Determination of Reduced Glutathione (GSH) Level
in Neutrophils. Reduced glutathione estimation in the cell
lysate was performed by the method of Moron et al. 1979
[37]. The required amount of the cell lysate was mixed with
25% of trichloroacetic acid and centrifuged at 2,000g for
15min to settle the precipitated proteins. The supernatant
was aspirated and diluted to 1mL with 0.2M sodium phos-
phate buﬀer (pH 8.0). Later, 2mL of 0.6mM DTNB was
added. After 10min the optical density of the yellow-colored
complexformedbythereactionofGSHandDTNB(Ellman’s
reagent) was measured at 405nm. A standard curve was ob-
tained with standard reduced glutathione. The levels of GSH
were expressed as μgo fG S H / m gp r o t e i n .
2.8.5. Determination of Oxidized Glutathione (GSSG) Level
in Neutrophils. The oxidized glutathione level was measured
after derivatization of GSH with 2-vinylpyidine according
to the method of Griﬃth, 1980 [38]. In brief, with 0.5mL
cell lysate, 2μL 2-vinylpyidine was added and incubated
for 1hr at 37◦C. Then the mixture was deprotienized with
4% sulfosalicylic acid and centrifuged at 1,000g for 10min
to settle the precipitated proteins. The supernatant was
aspirated and GSSG level was estimated with the reaction of
DTNB at 412nm in spectrophotometer and calculated with
standard GSSG curve. The levels of GSSG were expressed as
μg of GSSG/mg protein.
2.8.6. Activity of Super Oxide Dismutase (SOD) in Neutro-
phils. SOD activity was determined from its ability to inhibit
the autooxidation of pyrogallol according to Mestro Del and
McDonald, 1986 [39]. The reaction mixture considered is
of 50mM Tris (hydroxymethyl) aminomethane (pH 8.2),
1mM diethylenetriamine penta acetic acid, and 20–50μLo f
cell lysate. The reaction was initiated by addition of 0.2mM
pyrogallol, and the absorbance is measured kinetically at
420nm at 25◦C for 3min. SOD activity was expressed as
unit/mg protein.
2.8.7. Activity of Catalase (CAT) in Neutrophils. Catalase ac-
tivity was measured in the cell lysate by the method of Luck,
1963 [40]. The ﬁnal reaction volume of 3mL contained
0.05M tris-buﬀer, 5mM EDTA (pH 7.0) and 10mM H2O2
(in 0.1M potassium phosphate buﬀe r ,p H7 . 0 ) .A b o u t5 0μL
aliquot of the cell lysates was added to the above mixture.
T h er a t eo fc h a n g eo fa b s o r b a n c ep e rm i na t2 4 0 n mw a s
recorded. Catalase activity was calculated by using the molar4 ISRN Pharmacology
extinction coeﬃcient of 43.6M−1 cm−1 for H2O2.C A Ta c -
tivity was expressed as unit/mg protein.
2.8.8. Activity of Glutathione Peroxidase (GPx) in Neutrophils.
The GPx activity was measured by the method of Paglia
and Valentine, 1967 [41]. The reaction mixture contained
50mM potassium phosphate buﬀer (pH 7.0), 1mM EDTA,
1mM sodium azide, 0.2mM NADPH, 1U glutathione
reductase, and 1mM reduced glutathione. The sample, after
itsaddition,wasallowedtoequilibratefor5minat25◦C.The
reaction was initiated by adding 0.1mL of 2.5mM H2O2.
Absorbance at 340nm was recorded for 5min. Values were
expressed as nmol of NADPH oxidized to NADP by using
the extinction coeﬃcient of 6.2 × 103M−1 cm−1 at 340nm.
The activity of GPx was expressed in terms of nmol NADPH
consumed/min/mg protein.
2.8.9. Activity of Glutathione Reductase (GR) in Neutrophils.
The GR activity was measured by the method of Miwa, 1972
[42]. The tubes for enzyme assay were incubated at 37◦C
a n dc o n t a i n e d2 . 0 m Lo f9 m MG S S G ,0 . 0 2 m Lo f1 2 m M
NADPH, Na4, 2.68mL of 1/15M phosphate buﬀer (pH 6.6),
and 0.1mL of cell lysate. The activity of this enzyme was
determined by monitoring the decrease in absorbance at
340nm. The activity of GR was expressed in terms of nmol
NADPH consumed/min/mg protein.
2.8.10. Activity of Glutathione-s-Transferase (GST) in Neu-
trophils. The activity of GST activity was measured by the
method of Habig et al. 1974 [43]. The tubes of enzyme
assaywereincubatedat25◦Candcontained2.85mLof0.1M
potassium phosphate (pH 6.5) containing 1mM of GSH,
0.05mL of 60mM 1-chloro-2,4-dinitrobengene, and 0.1mL
cell lysate. The activity of this enzyme was determined
by monitoring the increase in absorbance at 340nm. The
activityofGSTwasexpressedintermsofnmolN ADPHc on-
sumed/min/mg protein.
2.8.11.ProteinEstimation. Proteinwasdeterminedusingbo-
vine serum albumin as standard according to Lowry et al.
1951 [44].
2.9. Statistical Analysis. The experiments were performed
three times and the data are presented as mean ± S.E.M.
Comparisons of the means of control and experimental
groups were made by two-way ANOVA test (using a statis-
tical package, Origin 6.1, Northampton, MA 01060, USA)
with multiple comparison t-tests, P<0.05 as a limit of
significance.
3. Results
3.1. Nitrate (NO) Generation. Nitrite generation (NO) that
occurred by inducible nitric oxide synthase (iNOS) can then
combine with superoxide and be able to generate a prod-
uct which has much more toxicity such as peroxynitrite
(ONOO−). NO generation was signiﬁcantly (P<0.05) in-
creasedinVSSA-andVRSA-infectedneutrophilsby135.45%
and 145.32%, respectively in compare with control, which
was also signiﬁcantly (P<0.0 5 )d e c r e a s e di nn a n o c o n j u -
gated vancomycin-treated group by 46.30% and 49.44%. It
was observed from our study that treatment of vancomycin
signiﬁcantly (P<0.05) decreased the NO generation by
32.68%inVSSAinfection,whereas5.64%inVRSAinfection,
which was not signiﬁcant (Figure 1).
3.2. Lipid Peroxidation Level. Lipid peroxidation is an im-
portant determinant to access the cellular damage. Lipid
peroxidation in terms of malondialdehyde level was signifi-
cantly (P<0.05) increased in neutrophils by 145.28% and
186.48%, respectively, due to VSSA and VRSA infection as
compared to control group, which was signiﬁcantly (P<
0.05) decreased by 44.52% and 45.37%, respectively, due
to treatment of nanoconjugated vancomycin. Treatment of
vancomycin decreased MDA levels signiﬁcantly (P<0.05)
in VSSA-infected neutrophils by 34.39%, whereas 4.59%
in VRSA-infected neutrophils which was not signiﬁcant
(Figure 2).
3.3. Protein Oxidation Level. Protein oxidation in terms of
protein carbonyls (PC) is an important determination of
cellular injury. Protein carbonyl level was signiﬁcantly (P<
0.05) increased in neutrophils by 140.38% and 187.44%,
respectively,duetoVSSAandVRSAinfectionascomparedto
control group, which was signiﬁcantly (P<0.05) decreased
by 45.19% and 46.94%, respectively, due to treatment of
nanoconjugated vancomycin. Treatment of vancomycin de-
creased PC levels signiﬁcantly (P<0.05) in VSSA-infected
neutrophils by 33.81%, whereas 10.89% in VRSA-infected
neutrophils which was not signiﬁcant (Figure 2).
3.4. Reduced and Oxidized Glutathione Level. Glutathione is
an important antioxidant in cellular system. So, to under-
stand glutathione level, we have measured both reduced and
oxidized form of glutathione. Reduced glutathione level was
signiﬁcantly (P<0.05) diminished in neutrophils by 67.50%
and 53.04%, respectively, due to VSSA and VRSA infection
as compared to control group, which was signiﬁcantly (P<
0.05) increased by 161.62% and 91.98% due to treatment
of nanoconjugated vancomycin. Treatment of vancomycin
increased reduced glutathione level signiﬁcantly (P<
0.05) in VSSA-infected neutrophils by 128.14%, whereas
3.84% in VRSA-infected neutrophils which is not signiﬁcant
(Figure 3). Oxidized glutathione level was signiﬁcantly (P<
0.05) elevated in neutrophils by 90.11% and 103.64%, re-
spectively, due to VSSA and VRSA infection as compared to
control group, which was signiﬁcantly (P<0.05) decreased
by 40.64% and 38.43% due to treatment of nanoconjugated
vancomycin. Treatment of vancomycin decreased oxidized
glutathione level signiﬁcantly (P<0.05) in VSSA-infected
neutrophils by 23.01%, whereas 5.15% in VRSA-infected
neutrophils which was not signiﬁcant (Figure 3).
3.5. Superoxide Dismutase (SOD) Activity. Superoxide dis-
mutase catalyzes the breakdown of superoxide radical intoISRN Pharmacology 5
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oxygen and hydrogen peroxide. SOD activity was signifi-
cantly (P<0.05) diminished in neutrophils by 44.03%,
and 35.31%, respectively, due to VSSA and VRSA infection
as compared to control group, which was signiﬁcantly
(P<0.05) increased by 67.16% and 40.09% due to treat-
ment of nanoconjugated vancomycin. Treatment of van-
comycin increased SOD activity signiﬁcantly (P<0.05)
in VSSA-infected neutrophils by 39.24%, whereas 11.25%
in VRSA-infected neutrophils which was not signiﬁcant
(Figure 4).6 ISRN Pharmacology
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3.6. Catalase (CAT) Activity. Catalase catalyzes the conver-
sion of hydrogen peroxide to oxygen and water. CAT activity
was signiﬁcantly (P<0.05) decreased in neutrophils by
61.40% and 56.47%, respectively, due to VSSA and VRSA
infection as compared to control group, which was signif-
icantly (P<0.05) increased by 99.44% and 123.04% due
to treatment of nanoconjugated vancomycin. Treatment of
vancomycin increased CAT activity signiﬁcantly (P<0.05)
in VSSA-infected neutrophils by 24.99%, whereas 1.36%
in VRSA-infected neutrophils which was not signiﬁcant
(Figure 4).
3.7. Glutathione Peroxidase (GPx) Activity. The glutathione
peroxidase (GPx) activity was measured to understand the
antioxidant enzyme status of diﬀerent experimental group of
neutrophils. GPx activity was signiﬁcantly (P<0.05) dimin-
ishedinneutrophilsby74.17%and75.70%,respectively,due
to VSSA and VRSA infection as compared to control group,
which was signiﬁcantly (P<0.05) increased by 217.13% and
248.95% due to treatment of nanoconjugated vancomycin.
Treatment of vancomycin increased GPx activity significant-
ly (P<0.05) in VSSA-infected neutrophils by 155.94%,
whereas 8.42% in VRSA-infected neutrophils which was not
significant (Figure 5).
3.8. Glutathione Reductase (GR) Activity. The glutathione
reductase (GR) activity was measured to understand the
antioxidant enzyme status of diﬀerent experimental group
of neutrophils. GR activity was signiﬁcantly (P<0.05) de-
creased in neutrophils by 56.17% and 57.19%, respectively,
due to VSSA and VRSA infection as compared to control
group, which was signiﬁcantly (P<0.05) increased by
104.65% and 111.96% due to treatment of nanoconjugated
vancomycin. Treatment of vancomycin increased GR activity
signiﬁcantly (P<0.05) in VSSA-infected neutrophils by
58.64%, whereas 4.74% in VRSA-infected neutrophils which
was not signiﬁcant (Figure 5).
3.9. Glutathione-s-Transferase (GST) Activity. The glutathio-
ne-s-transferase (GST) activity was measured to understand
the antioxidant enzyme status of diﬀerent experimental
group of neutrophils. GST activity was signiﬁcantly (P<
0.05) diminished in neutrophils by 50.13% and 50.62%,
respectively,duetoVSSAandVRSAinfectionascomparedto
control group, which was signiﬁcantly (P<0.05) increased
by 73.62% and 78.38% due to treatment of nanoconjugated
vancomycin. Treatment of vancomycin increased GST activ-
ity signiﬁcantly (P<0.05) in VSSA-infected neutrophils by
48.0%, whereas 6.35% in VRSA-infected neutrophils which
was not signiﬁcant (Figure 5).
4. Discussion
Nature has provided cells with very strong biological anti-
oxidant defense mechanisms. These include a variety of en-
zymatic and nonenzymatic molecules with enormous capa-
bilities to mitigate the deleterious and potentially harmful
eﬀects of ROS and other free radicals. One of the primary
antioxidant defense mechanisms is the GSH redox system.
The enzymes of this system provide a formidable protective
shieldagainstoxidativedamage.Alterationsintheiractivities
ultimately may result in irreversible manifestation of cellular
damage [45]. In this context, our present study proves to be
more relevant and will help further study in investigating theISRN Pharmacology 7
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protectiveroleofnanoconjugatedvancomycinagainstVSSA-
and VRSA-induced oxidative stress in neutrophils.
CMC-EDBE-FA nanoparticle was prepared by the car-
boxylic group (–COOH) of folic acid and –COOH group
offunctionalizedcarboxymethylchitosanconnectedthrough
the end-amino groups hydrophilic spacer, 2,2 -(ethylenedi-
oxy)-bis-ethylamine. It is well known that carboxymethyl
chitosaniseasilysolubleinwaterbutfolicacidisverylesssol-
ubility in water. When carboxymethyl chitosan is connected
by folic acid through a spacer, carboxymethyl chitosan may
act as a hydrophilic part and folic acid as a hydrophobic part.
It is evident from our study that, in vivo VSSA and VRSA8 ISRN Pharmacology
infection in neutrophils of mice is associated with enhanced
nitrate generation, MDA level, PC level, GSSG level, and
decreased GSH level and as well as decreased enzymatic
antioxidant (SOD, CAT, GPx, GR, and GST) activity, which
areamelioratedbytreatmentofnanoconjugatedvancomycin
(Figures 1–5).
Inthisstudy,signiﬁcantelevationofnitrategenerationin
neutrophils was observed in VSSA- and VRSA-infected mice.
Treatment of nanoconjugated vancomycin to VSSA- and
VRSA-infectedmicedecreasedtheNOgeneration(Figure 1).
Nitric oxide (NO) is a free radical synthesized by nitric oxide
synthase (NOS). NOS is composed of two identical mono-
mers with molecular weights ranging from 130 to 160kDa
[46]. Our previous study shown that nitric oxide synthesis in
lymphocytes and as well as release in serum is high during
VSSA and VRSA infection, which can be related to an al-
teration in oxidant-antioxidant potential [28]. Thus, higher
level of nitrite generation by VSSA and VRSA infection may
be due to high production of ROS. Nanoconjugated van-
comycin plays the role of antioxidant to prevent the nitrate
generation may be through the inhibition of inducible nitric
oxide synthase (iNOS) expression [47]. Thus, in addition to
the cellular antioxidant system, nanoconjugated vancomycin
may indirectly protect neutrophils from VSSA and VRSA
infection induced cellular changes. Thus, free radical deple-
tion by the antioxidant agents seems to be beneﬁcial for pre-
venting the damage of lipid and protein.
In this study, signiﬁcant elevation of malondialdehyde
(MDA) and protein carbonyl level was observed in neu-
trophils of VSSA- and VRSA-infected mice. Treatment of
nanoconjugated vancomycin to VSSA- and VRSA-infected
mice decreased lipid peroxidation and protein oxidation
signiﬁcantly in neutrophils (Figure 2). It may be due to
the generation of free radicals (mainly NO) which may
react with protein in addition to lipids. Lipid peroxidation
is known to disturb the integrity of cellular membranes
leading to the leakage of cytoplasmic enzymes [48]. Protein
carbonyls formation has been indicated to be an earlier
marker of protein oxidation. Oxidation of protein may be
due to either excessive oxidation of proteins or decreased
capacity to cleanup oxidative damaged proteins. Oxidative
modiﬁcation of proteins may lead to the structural alteration
andfunctionalinactivationofmanyenzymeproteins[49],as
evidenced by the decreased activity of diﬀerent antioxidant
enzymes like SOD, CAT, GPx, GR, and GST.
Reactive oxygen species (ROS) are generated during
oxidative metabolism and can inﬂict damage on all classes of
cellular macromolecules and eventually leading to cell death.
Anelevationinfreeradicalformationcanbeaccompaniedby
an immediate compensatory increase in the activities of the
free radical scavenging enzymes [50]. Imbalance between the
generation of reactive oxygen species (ROS) and the antiox-
idant system causes oxidative stress. Glutathione, an impor-
tant cellular reductant, is involved in protection against free
radicals, peroxides, and toxic compounds in cellular systems
[51]. In the present study, the reduced glutathione level was
signiﬁcantly decreased in neutrophils of VSSA- and VRSA-
infected mice. Treatment of nanoconjugated vancomycin to
VSSA- and VRSA-infected mice increased the GSH level
(Figure 3). In this study, it was observed that oxidized
glutathione level was increased in VSSA- and VRSA-infected
neutrophils, which was ameliorated due to nanoconjugated
vancomycin treatment (Figure 3). The decreased GSH levels
represent its increased utilization due to VSSA and VRSA
infection. On the other hand, decreasing GSH level may be
due to increasing level of lipid oxidation products which may
beassociatedwithlessavailabilityofNADPHrequiredforthe
activity of glutathione reductase (GR) to transform GSSG to
GSH [52] due to the increasing production of ROS in form
of NO. In our present study, the increasing levels of GSSG
anddecreasingGRactivity(Figure 5)duetoVSSAandVRSA
infection may support the explanation.
Antioxidant enzymes are considered to be a primary
defense that prevents biological macromolecules from ox-
idative damage. SOD rapidly dismutates superoxide anion
(O2
•−)t ol e s sd a n g e r o u sH 2O2, which is further degraded
by CAT and GPx to water and oxygen [53]. The results
of the present study showed a signiﬁcant fall in SOD and
CAT activities in neutrophils of VSSA- and VRSA-infected
group. Treatment of nanoconjugated vancomycin to VSSA-
and VRSA-infected mice signiﬁcantly increased the SOD and
CAT activity in neutrophils (Figure 4). SOD, dismutate O2
•−
and the same in turn is a potent inhibitor of CAT [54]. The
depletion in SOD activity may be due to dispose oﬀ the
free radicals, produced due to VSSA and VRSA infection.
Besidethis,duringinfection,H2O2 producedbydismutation
of superoxide anion may have been eﬃciently converted to
O2 by CAT and the enzyme activities showed a marked
reduction. The depletion of antioxidant enzyme activity may
be due to inactivation of the enzyme proteins by VSSA and
VRSA infection induced NO generation, depletion of the
enzyme substrates, and/or downregulation of transcription
and translation processes.
GPx works nonspeciﬁcally to scavenge and decompose
excess hydroperoxides including H2O2, which may be preva-
lent under oxidative stress [55–57]. Glutathione-s-transfer-
ase (GST) mainly detoxiﬁes electrophilic compounds [58]
and has a well-established role in protecting cells from muta-
gens and carcinogens as a free-radical scavenger along with
glutathione. In the present study, the signiﬁcant decreasing
of GSH level and GSH-dependent enzymes, that is, GPx,
GR, and GST (Figure 5) in neutrophils of VSSA and VRSA
infection may be due to increased utilization to scavenge
the free-radical generation. Treatment of nanoconjugated
vancomycin to VSSA- and VRSA-infected mice signiﬁcantly
increased the GPx, GR, and GST activity in neutrophils
(Figure 5).
In conclusion, the study described here, neutrophils are
susceptible to S. aureus infection through the increased pro-
duction of nitric oxide which leads to decreased antioxidant
status in cell and nanoconjugated vancomycin protects the
neutrophils from such infection by decreasing NO genera-
tion, lipid, and protein damage and also by increasing the
antioxidant status. Hence, the nanoconjugated vancomycin
may be used as a potent free-radical scavenger antioxidative
product and as well as a potential therapeutic agent against
staphylococcal infection.ISRN Pharmacology 9
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